Results 191 to 200 of about 4,030,855 (263)

Sample size calculation in three-arm equivalence trials including a placebo for binary clinical endpoints. [PDF]

iScience
Yu F, Ji S, Xiao Z, Zhao X, Zhong J.
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

Finite sample size errors in the context of multiple error sources in quantitative medical imaging: An evaluation for breast magnetic resonance diffusion-weighted imaging. [PDF]

PLoS One
Eberle JV, Bickelhaupt S, Kapsner LA, Ohlmeyer S, Wenkel E, Uder M, Skwierawska D, Tkotz K, Hadler D, Kuder TA, Laun FB.   +10 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, EarlyView.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Exploring Centiloid Robustness: Impact of Sample Size and Image Resolution on Centiloid Conversion Accuracy. [PDF]

J Nucl Med
Zhang J, Soleimani-Meigooni DN, Koeppe R, Ackley S, Schonhaut DR, Lin ZE, Maiti P, Yballa C, Rocha S, Shankar R, Amuiri A, Bourgeat P, Doré V, Carrillo MC, Dickerson BC, Apostolova LG, Harrison TM, Grinberg LT, Spina S, Seeley WW, Rabinovici GD, La Joie R, Blazhenets G, LEADS Consortium and Alzheimer’s Disease Neuroimaging Initiative.   +23 more
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

A tutorial on conducting sample size and power calculations for detecting treatment effect heterogeneity in cluster randomized trials with linear mixed models. [PDF]

Int J Epidemiol
Ryan Baumann M, Taljaard M, Heagerty PJ, Harhay MO, Tong G, Wang R, Li F.   +6 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Psychometric Network Model Recovery: The Effect of Sample Size, Number of Items, and Number of Nodes. [PDF]

Eur J Investig Health Psychol Educ
Ávalos-Tejeda M, Calderón C.
europepmc   +1 more source